Drug data last refreshed 2m ago · AI intelligence enriched 6d ago
DELFEN is a vaginal aerosol contraceptive foam containing nonoxynol-9, a spermicide that immobilizes and kills sperm to prevent pregnancy. It is a topical, non-hormonal birth control option applied intravaginally prior to intercourse. The product represents an older generation of over-the-counter contraceptive technology with limited modern clinical adoption.
Product approaching loss of exclusivity with minimal linked career opportunities, indicating a mature/declining brand with limited commercial team expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Nonoxynol-9 (N-9) and HIV Infection
DELFEN represents a legacy product with minimal active career development opportunities, as evidenced by zero linked job postings. Professionals joining this franchise should expect small, maintenance-focused teams and should position themselves for portfolio transitions as the product approaches end-of-life.
Worked on DELFEN at Personal Genomics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.